For much of its life, the telehealth company Ro was known as a provider of sexual wellness treatments. Then it drastically reshaped its business and pivoted to offering weight-loss drugs like Wegovy and Zepbound as part of a health care revolution.
Now, the nine-year-old privately held company is offering a closer look at the results of that transition.
Ro announced on Wednesday that it had more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022.
For Zachariah Reitano, a Ro founder and its chief executive, the results underscore both the efficacy of the company’s overhaul and the huge draw of GLP-1 drugs, which can offer benefits beyond weight loss.
“People will ask me, ‘Are you just GLP-1s now?’” he said in an interview. “And my response is, ‘Just? Like, just working on the leading causes of death?’”
The company’s turnaround may also spur questions about whether Ro, which has not raised new money from investors in years, will eventually go public, following in the footsteps of its rival Hims & Hers.
Mr. Reitano also chalked up the company’s success to what he called a badly needed reset. That came months after the company raised $500 million at a $5 billion valuation in spring 2021.
At the time, its growth had plateaued at just 9 percent year-on-year-growth, in part because the company had tried to do too much and lost sight of its longer-term ambitions. “We were not going to die, but we were not growing,” Mr. Reitano said. “We were just really a zombie company.”
What came next, Mr. Reitano said, was what he called a “re-founding” of Ro. That meant building what he called a “strong attract-repel culture” to inspire the right kinds of employees, shutting more than 10 product lines and ditching longer-term product road maps.
It also involved job cuts: By June 2022, the company had laid off about 20 percent of its work force, and another founder, Rob Schutz, stepped back from an executive role to an advisory one. (Mr. Reitano defended the need to reduce the head count, but added, “I do think Silicon Valley glorifies layoffs in a way they shouldn’t.”)
By 2023, Ro leaned into the rising popularity of GLP-1 drugs, introducing its Ro Body subscription service to help customers obtain treatments and navigate the insurance process.
Ro has also began featuring celebrity endorsements of its weight-loss treatments, including a Super Bowl ad this year featuring the tennis star Serena Williams talking about the drugs’ health benefits. (Her husband, the technology executive Alexis Ohanian Sr., is a Ro investor and board member.)
The spot drew attention to Ro — but perhaps not in a positive way, ranking near the bottom of a survey by USA Today of Super Bowl ads. Mr. Reitano defended the ad: “What she did took tremendous courage,” he said, adding that it helped persuade more consumers to seek GLP-1 treatments.
While the company became known in recent years for providing generic versions of GLP-1s during a shortage of drugs like Wegovy, Mr. Reitano emphasized that the company had always worked directly with Novo Nordisk and Eli Lilly, the pharmaceutical giants behind Wegovy and Zepbound. He claims that Ro is now the largest provider of branded GLP-1 drugs in the United States.
Selling branded drugs has taken a toll on telehealth companies’ margins: Hims this week lowered its earnings guidance for the year as it emphasizes nongeneric offerings, while analysts at Barclays foresaw a nearly halving of adjusted profit margins at Hims.
At the same time, both Novo Nordisk and Eli Lilly have been building up their own direct-to-consumer businesses as well as working with Ro.
But Mr. Reitano defended Ro’s business model, arguing that the company expected to maintain higher margins because of its subscriptions and its cost efficiency. He added that Ro had cut the cost of its membership plans, passing the savings onto customers.
Artificial intelligence will play a big role, too, he said, including speeding up customer service queries and better personalizing a consumer’s medical treatment. A.I., for instance, could recommend that a patient change an injection schedule based on workouts.
Does the future of Ro also involve going public, as many analysts expect? Mr. Reitano demurred, saying that the company was able to fund its business from its operations and could be profitable if it chose to be.
But, he added, “sometimes the best time to raise money is when you don’t need it.”